Welcome to our dedicated page for REBUS HLDGS news (Ticker: RBSH), a resource for investors and traders seeking the latest updates and insights on REBUS HLDGS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REBUS HLDGS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REBUS HLDGS's position in the market.
Inspyr Therapeutics, Inc. announces a 1-for-75 reverse stock split and a restructuring to become Rebus Holdings, Inc., trading under the symbol RBSH. This transformation aims to enhance shareholder value and streamline operations, particularly focusing on its lead asset RT-AR-001. Following a pre-IND meeting with the FDA, the company plans to advance manufacturing and non-clinical studies. The reverse split is designed to facilitate a potential listing on the OTCQB and later on a national exchange to improve liquidity and capital access.
FAQ
What is the market cap of REBUS HLDGS (RBSH)?
